Xencor INC

Xencor resolves a U.S. royalty dispute with Alexion, securing $105 million and extending its operational runway through 2028.

Xencor, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors, ratification of its auditor, and approval of an equity incentive plan amendment.

Xencor announced first quarter 2026 financial results, highlighting progress in its oncology and autoimmune pipelines with key data presentations and study initiations planned for the second half of 2026.

Xencor presented final Phase 1 data for XmAb942 and preclinical data for XmAb412, highlighting potential best-in-class profiles for inflammatory bowel disease treatments.

Xencor, Inc. has adopted a new Executive Severance Policy providing specific benefits to certain executives upon termination under defined circumstances.

Xencor announced that Alexion Pharmaceuticals will cease US royalty payments for Ultomiris, impacting Xencor's projected revenue by $100-$120 million through 2028.

Xencor reports a significant decrease in Q1 2026 revenue driven by a royalty dispute with Alexion, alongside increased R&D spending.

Biopharmaceutical company Xencor reports significantly increased revenue and a narrowed net loss for Q3 and the first nine months of 2025, driven by milestone payments and royalties, despite ongoing R&D investments.

Xencor, Inc. reported significantly increased revenue for the second quarter and first half of 2025, driven by milestone payments and royalties, while advancing multiple clinical-stage antibody therapeutics.

Xencor, Inc. announces its financial results for the first quarter of 2025, highlighting revenue growth and progress in its clinical-stage biopharmaceutical programs.

Xencor, Inc. restated its previously issued financial statements for fiscal year 2023 and the first three quarters of 2024 due to errors in accounting for a royalty transaction, research and development expenses, and state tax obligations, leading to a re-evaluation of internal controls.

Xencor restated its previously issued financial statements for the year ended December 31, 2023, and the three and six months ended June 30, 2024, due to errors in accounting for a royalty transaction, research and development expenses, and state tax obligations.

Xencor, a clinical-stage biopharmaceutical company, reported a net loss of $91.9 million in 2025, driven by increased R&D, while advancing multiple oncology and autoimmune drug candidates and remediating prior material weaknesses in internal controls.

Xencor's 2024 10-K filing highlights a strategic focus on T-cell engaging bispecific antibodies, provides updates on its clinical pipeline, and outlines its financial position and future outlook.

Xencor restated its 2023 financial statements due to errors in royalty accounting and tax treatment, leading to the identification of material weaknesses in internal controls.

Xencor and Genentech have amended their collaboration agreement, transitioning from a cost-sharing model to a royalty and milestone-based structure effective June 1, 2024.

Director Ellen Feigal acquired 10,302 shares of common stock and was granted options for 20,604 shares in a transaction on June 16, 2026.

Xencor Inc. reports a Form 4 filing detailing insider Kevin Charles Gorman's acquisition of restricted stock units and stock options.

Xencor Director Kurt A. Gustafson acquired 10,302 shares of common stock and was granted options for 20,604 shares, with vesting schedules detailed.

Xencor Director Barbara Klencke acquired 10,302 shares of common stock and was granted options for 20,604 shares, with specific vesting schedules outlined.

Alan Bruce Montgomery of Xencor reports acquisition of 10,302 common shares and grant of stock options for 20,604 shares.

Richard J. Ranieri of Xencor Inc. acquired 10,302 shares of common stock and was granted options for 20,604 shares, with vesting schedules detailed.

Xencor Inc. is holding its 2026 Annual Meeting of Stockholders on June 16, 2026, to elect directors, ratify auditors, and vote on an amendment to increase shares available under its 2023 Equity Incentive Plan.

Xencor, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission (SEC) regarding its upcoming shareholder meeting.

Xencor is asking stockholders to approve an amendment to its 2023 Equity Incentive Plan to increase the number of authorized shares by 3,000,000.

Xencor, Inc. has filed a definitive proxy statement with the SEC.

Xencor's 2024 proxy statement outlines key proposals for the annual stockholder meeting, including director elections, auditor ratification, and executive compensation approval, while emphasizing the company's strategic focus on T-cell engager programs and commitment to strong corporate governance.

Vanguard Capital Management has reported a beneficial ownership of 5.13% in Xencor Inc., holding 3,810,823 shares as of June 30, 2026.

EcoR1 Capital, LLC and Oleg Nodelman have filed a Schedule 13G reporting a 2.9% beneficial ownership stake in Xencor Inc.

RA Capital Management and its affiliates have reported a 6.5% beneficial ownership stake in Xencor, Inc., totaling 4,736,739 shares of common stock.

The Vanguard Group has reported 0% beneficial ownership in Xencor Inc. following an internal realignment that shifts reporting to its subsidiaries.

State Street Corporation has reported a 6.3% beneficial ownership stake in Xencor Inc. common stock as of December 31, 2025.

The Vanguard Group has reported an increased beneficial ownership of Xencor Inc. common stock, now holding 10.03% of the class.